Page 7 - Pharmaceutical

LIVE: UN Yoga Day celebration makes to Guinness World Record book

Catch all the live updates from across the globe here

Natco gets USFDA approval for Tipiracil Hydrochloride, Trifluridine Tablets

Shares of Natco Pharma Ltd, on Friday, fell over 1 per cent at Rs 632 on BSE

Need sectoral strategies to enhance export competitiveness: IIPMB Director

There is a need to develop sectoral strategies for enhancing export competitiveness, especially for electronics, engineering, pharmaceutical, and high-tech industries with a view to increase India's outbound shipments to USD 2 trillion by 2030, a trade expert said on Tuesday. To achieve the target of USD 2 trillion in services and goods exports by 2030, India requires an export growth of 14.5 per cent per annum. "Competitiveness across the exports value chain is the key to India's exports growth and its sustainability. In addition to generalised strategies, India needs to evolve sectoral strategies for export competitiveness, especially for engineering goods, pharmaceutical, electronics, and high-tech industries," Indian Institute of Plantation Management Bengaluru (IIPMB) Director Rakesh Mohan Joshi said. Sectors like polished diamonds, jewellery, passenger cars, telecommunication equipment would help in increasing the shipments. In terms of countries, tremendous unexplored potent

Dr Reddy's completes Phase-I study in proposed biosimilar of tocilizumab

Global Phase III study is being initiated to compare the efficacy, safety, tolerability and immunogenicity of DRL_TC with the reference product

From June 1, cough syrups must be tested at govt labs before export

Presently over 80% of the antiretroviral drugs used globally to combat AIDS are supplied by Indian pharmaceutical firms

Dispute between two promoters not to impact corporate performance: Hikal

Pharmaceuticals and crop protection firm Hikal Ltd on Thursday refuted allegations by proxy advisory firm InGovern Research Services that the battle between its two promoters is impacting corporate performance. Hikal is in the midst of a battle between two promoter groups -- the Hiremaths who own 34.84 per cent stake and Baba N Kalyani (BNK)-led side that holds 34.01 per cent of the company. Minority shareholders own 31.15 per cent. InGovern in a note to shareholders had stated that in the absence of an agreement between the two warring promoter groups due the proportion of shareholding makes it difficult for any special resolution to be passed. It was also likely to slow down decision-making and resultantly, the interest of the company is likely to be compromised. In a detailed response to points raised by InGovern, Hikal said, "The document is a one-sided and an ill-informed attempt to damage the credibility of the company and its management and has been made with the intention of

Zydus Lifesciences gets final approval from USFDA to manufacture ulcer drug

Sucralfate Tablets USP, 1 gram had annual sales of $84 million in the United States

Mankind Pharma IPO opens today: Check GMP, price band, other details here

Mankind Pharma IPO listing date: The IPO is likely to list on NSE and BSE on May 8

Licences of 18 pharma firms cancelled for manufacturing spurious drugs

In a major crackdown against the manufacture of substandard drugs, central and state regulators conducted joint inspections at 76 pharma companies and cancelled the licences of 18 of them for producing spurious and adulterated drugs, official sources said on Tuesday. The inspections were carried out across 20 states and Union territories in the past 15 days, they said. A source said that the action has been taken against 76 companies in the first phase of a special drive against the manufacture of substandard drugs. "Licences of 18 pharma companies have been cancelled for manufacturing spurious and adulterated drugs and for violating GMP (good manufacturing practice).... Besides, 26 firms have been given show-cause notices," an official source said. The sources said that as part of the special drive, the regulators have identified 203 firms. A majority of the companies are from Himachal Pradesh (70), followed by Uttarakhand (45) and Madhya Pradesh (23). Recently, questions have b

Key brands, new launches to sustain Abbott India's outperformance

Margins to remain healthy on the back of cost-saving measures

India taking steps to counter manufacture of illegal synthetic drugs: INCB

INCB chief Jagjit Pavadia said, "India has witnessed the rise of commercial chemical factories that have been adapted to illicitly manufacture large quantities of synthetic drugs and their precursors"

Bristol Myers Squibb to invest Rs 800 cr for drug development in Hyderabad

Bristol Myers Squibb, a world's leading biopharmaceutical company will establish a state of-the-art site here to expand its global drug development and IT capabilities with an investment of Rs 800 crore, a Telangana government press release said on Thursday. The announcement was made after Telangana Minister KT Rama Rao's meeting with Samit Hirawat, Executive Vice-President, Global Drug Development at BMS, who is in the city to participate in BioAsia 2023, it said. The company plans to begin operations in Hyderabad later in 2023, with the potential over the next few years to employ approximately 1,500 people who will be engaged in cutting-edge Research and Development and digital activities, a BMS release said. Rama Rao said, "I am delighted to welcome Bristol Myers Squibb to the vibrant ecosystem of Hyderabad. It is indeed a matter of pride that BMS, which is one of the most innovative and world leading biopharmaceutical companies, has chosen Hyderabad and I strongly believe this .

Boosting pharma research

Govt should not solely depend on monetary incentives

Corporate India gears up to hedge China supply risk amid Covid surge

The sectors in India that import from China include pharmaceutical (pharma), automotive (auto), textile, engineering, and electronic goods

Domestic, semi-regulated markets to drive pharmaceutical industry's growth

High raw material prices to put pressure on margins

Advent International to pick up 50.1% in Suven Pharma for Rs 6,313 crore

To launch open offer for another 26%; plans merger with Cohance

Alembic Pharma gets USFDA nod for generic drug to treat breast cancer

Alembic Pharmaceuticals on Monday said it has received final approval from the US health regulator for its generic Fulvestrant injection used in treatment of breast cancer. The approval granted by the US Food & Drug Administration (USFDA) is for the abbreviated new drug application (ANDA), Fulvestrant injection of strength 250 mg/5 mL (50 mg/mL) per single-dose prefilled syringe, the company said in a statement. The approved injection is therapeutically equivalent to the reference listed drug product (RLD), Faslodex Injection, of AstraZeneca Pharmaceuticals LP, it added. Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of breast cancer, the company said. For 12 months ended September 2022, Fulvestrant injection, 250 mg/5 mL, had an estimated market size of USD 71 million, the company said citing IQVIA data.

Maiden Pharma's cough syrups are safe, WHO jumped the gun: DCGI

'Irreparable damage' to Indian pharma's global image, drug regulator writes to WHO

Rising cost of raw materials a challenge for drug firms: Cipla's Hamied

Companies will have to manage work to match India's National List of Essential Medicines but it will be worth the endeavour, she says

Fosun's sale of Gland Pharma to become India's biggest pharma deal: Report

With the acquisition, Gland pharma may also get access to global companies like AstraZeneca, Sanofi, Mylan, and Organon